This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sjöblom, T. Articles by Heldin, C.-H. Search for Related Content PubMed PubMed Citation Articles by Sjöblom, T. Articles by Heldin, C.-H.

Growth Inhibition of Dermatofibrosarcoma Protuberans Tumors by the Platelet-derived Growth Factor Receptor Antagonist STI571 through Induction of Apoptosis

Ludwig Institute for Cancer Research, S-751 24 Uppsala, Sweden [T. S., A. S., K. P. O., A. Ö., C-H. H.]; Department of Molecular Medicine, Clinical Genetics Unit, Karolinska Hospital, S-171 76 Stockholm, Sweden [K. P. O., J. P. D.]; Centre for Human Genetics, University of Leuven, B-3000 Leuven, Belgium [P. D. C.]; and Novartis Pharma AG, Oncology Research, CH-4002 Basel, Switzerland [E. B.]

Dermatofibrosarcoma protuberans (DFSP) and giant cell fibroblastoma (GCF) are recurrent, infiltrative skin tumors that presently are treated with surgery. DFSP and GCF tumors are genetically characterized by chromosomal rearrangements fusing the collagen type I1 (COLIA1) gene to the platelet-derived growth factor B-chain (PDGFB) gene. It has been shown that the resulting COL1A1/PDGF-B fusion protein is processed to mature PDGF-BB. Autocrine PDGF receptor stimulation has therefore been predicted to contribute to DFSP and GCF tumor development and growth. Here we demonstrate presence of activated PDGF receptors in primary cultures derived from six different DFSP and GCF tumors. Three of the primary cultures were further characterized; their in vitro growth displayed an increased sensitivity to treatment with the PDGF receptor tyrosine kinase inhibitor STI571, as compared with normal fibroblasts. Transplantable tumors, displaying a DFSP-like histology, were established from one of the DFSP primary cultures. Treatment of tumor-bearing severe combined immunodeficient mice with STI571 reduced tumor growth. The growth-inhibitory effects in vitro and in vivo occurred predominantly through induction of tumor cell apoptosis. Our study demonstrates growth-inhibitory effects of PDGF receptor antagonists on human DFSP- and GCF-derived tumor cells and demonstrates that autocrine PDGF receptor stimulation provides antiapoptotic signals contributing to the growth of these cells. These findings suggest targeting of PDGF receptors as a novel treatment strategy for DFSP and GCF.

This article has been cited by other articles:

				J. Andrae, R. Gallini, and C. Betsholtz Role of platelet-derived growth factors in physiology and medicine Genes & Dev., May 15, 2008; 22(10): 1276 - 1312. [Abstract] [Full Text] [PDF]

				J. Gibbons, M. J. Egorin, R. K. Ramanathan, P. Fu, D. L. Mulkerin, S. Shibata, C. H.M. Takimoto, S. Mani, P. A. LoRusso, J. L. Grem, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 570 - 576. [Abstract] [Full Text] [PDF]

				G. McArthur Dermatofibrosarcoma Protuberans: Recent Clinical Progress Ann. Surg. Oncol., October 1, 2007; 14(10): 2876 - 2886. [Abstract] [Full Text] [PDF]

				G. Potikyan, R. O.V. Savene, J. M. Gaulden, K. A. France, Z. Zhou, E. S. Kleinerman, S. L. Lessnick, and C. T. Denny EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins Cancer Res., July 15, 2007; 67(14): 6675 - 6684. [Abstract] [Full Text] [PDF]

				M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72. [Abstract] [Full Text] [PDF]

				J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306. [Abstract] [Full Text] [PDF]

				O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289. [Abstract] [Full Text] [PDF]

				M. L. Tejada, L. Yu, J. Dong, K. Jung, G. Meng, F. V. Peale, G. D. Frantz, L. Hall, X. Liang, H.-P. Gerber, et al. Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor {alpha} Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma. Clin. Cancer Res., May 1, 2006; 12(9): 2676 - 2688. [Abstract] [Full Text] [PDF]

				C. Cutcliffe, D. Kersey, C.-C. Huang, Y. Zeng, D. Walterhouse, E. J. Perlman, and for the Renal Tumor Committee of the Children's On Clear Cell Sarcoma of the Kidney: Up-regulation of Neural Markers with Activation of the Sonic Hedgehog and Akt Pathways Clin. Cancer Res., November 15, 2005; 11(22): 7986 - 7994. [Abstract] [Full Text] [PDF]

				M. Fiore, R. Miceli, C. Mussi, S. Lo Vullo, L. Mariani, L. Lozza, P. Collini, P. Olmi, P. G. Casali, and A. Gronchi Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate J. Clin. Oncol., October 20, 2005; 23(30): 7669 - 7675. [Abstract] [Full Text] [PDF]

				A. Armulik, A. Abramsson, and C. Betsholtz Endothelial/Pericyte Interactions Circ. Res., September 16, 2005; 97(6): 512 - 523. [Abstract] [Full Text] [PDF]

				L. Xu, R. Tong, D. M. Cochran, and R. K. Jain Blocking Platelet-Derived Growth Factor-D/Platelet-Derived Growth Factor Receptor {beta} Signaling Inhibits Human Renal Cell Carcinoma Progression in an Orthotopic Mouse Model Cancer Res., July 1, 2005; 65(13): 5711 - 5719. [Abstract] [Full Text] [PDF]

				S. Basciani, M. Brama, S. Mariani, G. De Luca, M. Arizzi, L. Vesci, C. Pisano, S. Dolci, G. Spera, and L. Gnessi Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity Cancer Res., March 1, 2005; 65(5): 1897 - 1903. [Abstract] [Full Text] [PDF]

				G. A. McArthur, G. D. Demetri, A. van Oosterom, M. C. Heinrich, M. Debiec-Rychter, C. L. Corless, Z. Nikolova, S. Dimitrijevic, and J. A. Fletcher Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225 J. Clin. Oncol., February 1, 2005; 23(4): 866 - 873. [Abstract] [Full Text] [PDF]

				R. Potula, N. Dhillion, Y. Sui, C. A. Zien, K. Funa, D. Pinson, M. S. Mayo, D. K. Singh, O. Narayan, and S. Buch Association of Platelet-Derived Growth Factor-B Chain with Simian Human Immunodeficiency Virus Encephalitis Am. J. Pathol., September 1, 2004; 165(3): 815 - 824. [Abstract] [Full Text] [PDF]

				N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]

				M. Furuhashi, T. Sjoblom, A. Abramsson, J. Ellingsen, P. Micke, H. Li, E. Bergsten-Folestad, U. Eriksson, R. Heuchel, C. Betsholtz, et al. Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth Rate Cancer Res., April 15, 2004; 64(8): 2725 - 2733. [Abstract] [Full Text] [PDF]

				P Reichardt, U Schneider, C Stroszczynski, D Pink, and P Hohenberger Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate J. Clin. Pathol., February 1, 2004; 57(2): 215 - 217. [Abstract] [Full Text] [PDF]

				S. M. Apte, D. Fan, J. J. Killion, and I. J. Fidler Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma Clin. Cancer Res., February 1, 2004; 10(3): 897 - 908. [Abstract] [Full Text] [PDF]

				B. Peng, C. Dutreix, G. Mehring, M. J. Hayes, M. Ben-Am, M. Seiberling, R. Pokorny, R. Capdeville, and P. Lloyd Absolute Bioavailability of Imatinib (Glivec(R)) Orally versus Intravenous Infusion J. Clin. Pharmacol., February 1, 2004; 44(2): 158 - 162. [Abstract] [Full Text] [PDF]

				D. Matei, D. D. Chang, and M.-H. Jeng Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor {alpha} and Akt Inactivation Clin. Cancer Res., January 15, 2004; 10(2): 681 - 690. [Abstract] [Full Text] [PDF]

				K. Beppu, J. Jaboine, M. S. Merchant, C. L. Mackall, and C. J. Thiele Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression J Natl Cancer Inst, January 7, 2004; 96(1): 46 - 55. [Abstract] [Full Text] [PDF]

				R. F. Hwang, K. Yokoi, C. D. Bucana, R. Tsan, J. J. Killion, D. B. Evans, and I. J. Fidler Inhibition of Platelet-Derived Growth Factor Receptor Phosphorylation by STI571 (Gleevec) Reduces Growth and Metastasis of Human Pancreatic Carcinoma in an Orthotopic Nude Mouse Model Clin. Cancer Res., December 15, 2003; 9(17): 6534 - 6544. [Abstract] [Full Text] [PDF]

				G. Vlahovic and J. Crawford Activation of Tyrosine Kinases in Cancer Oncologist, December 1, 2003; 8(6): 531 - 538. [Abstract] [Full Text] [PDF]

				K. Pietras, M. Stumm, M. Hubert, E. Buchdunger, K. Rubin, C.-H. Heldin, P. McSheehy, M. Wartmann, and A. Ostman STI571 Enhances the Therapeutic Index of Epothilone B by a Tumor-selective Increase of Drug Uptake Clin. Cancer Res., September 1, 2003; 9(10): 3779 - 3787. [Abstract] [Full Text] [PDF]

				P. Lindblom, H. Gerhardt, S. Liebner, A. Abramsson, M. Enge, M. Hellstrom, G. Backstrom, S. Fredriksson, U. Landegren, H. C. Nystrom, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall Genes & Dev., August 1, 2003; 17(15): 1835 - 1840. [Abstract] [Full Text] [PDF]

				C. A. London, A. L. Hannah, R. Zadovoskaya, M. B. Chien, C. Kollias-Baker, M. Rosenberg, S. Downing, G. Post, J. Boucher, N. Shenoy, et al. Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies Clin. Cancer Res., July 1, 2003; 9(7): 2755 - 2768. [Abstract] [Full Text] [PDF]

				T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor {beta} in Preclinical Models of Human Small Cell Lung Cancer Mol. Cancer Ther., May 1, 2003; 2(5): 471 - 478. [Abstract] [Full Text] [PDF]

				M. S. Merchant, C.-W. Woo, C. L. Mackall, and C. J. Thiele Potential Use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo Activity J Natl Cancer Inst, November 20, 2002; 94(22): 1673 - 1679. [Abstract] [Full Text] [PDF]

				E. C. McGary, K. Weber, L. Mills, M. Doucet, V. Lewis, D. C. Lev, I. J. Fidler, and M. Bar-Eli Inhibition of Platelet-derived Growth Factor-mediated Proliferation of Osteosarcoma Cells by the Novel Tyrosine Kinase Inhibitor STI571 Clin. Cancer Res., November 1, 2002; 8(11): 3584 - 3591. [Abstract] [Full Text] [PDF]

				I. Szymkiewicz, K. Kowanetz, P. Soubeyran, A. Dinarina, S. Lipkowitz, and I. Dikic CIN85 Participates in Cbl-b-mediated Down-regulation of Receptor Tyrosine Kinases J. Biol. Chem., October 11, 2002; 277(42): 39666 - 39672. [Abstract] [Full Text] [PDF]

				K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.-H. Heldin, and A. Ostman Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy Cancer Res., October 1, 2002; 62(19): 5476 - 5484. [Abstract] [Full Text] [PDF]

				S. Attoub, C. Rivat, S. Rodrigues, S. Van Bocxlaer, M. Bedin, E. Bruyneel, C. Louvet, M. Kornprobst, T. Andre, M. Mareel, et al. The c-kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy Cancer Res., September 1, 2002; 62(17): 4879 - 4883. [Abstract] [Full Text] [PDF]

				B. P. Rubin, S. M. Schuetze, J. F. Eary, T. H. Norwood, S. Mirza, E. U. Conrad, and J. D. Bruckner Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans J. Clin. Oncol., September 1, 2002; 20(17): 3586 - 3591. [Abstract] [Full Text] [PDF]

				J. L. Arbiser, B. Govindarajan, X. Bai, H. Onda, A. Kazlauskas, S. D. Lim, M. B. Amin, and L. Claesson-Welsh Functional Tyrosine Kinase Inhibitor Profiling : A Generally Applicable Method Points to a Novel Role of Platelet-Derived Growth Factor Receptor-{beta} in Tuberous Sclerosis Am. J. Pathol., September 1, 2002; 161(3): 781 - 786. [Abstract] [Full Text] [PDF]